Fw: FDA MedWatch - Topamax (topiramate) associated with hyperchloremi c, non-anion gap metabolic acidosis

[Guest guest]

If I am not mistaken, I believe some of you have used Topamax, so I thought

you might be interested in this.

Me

Nebraska, USA

mymocha@...

> MedWatch - The FDA Safety Information and Adverse Event Reporting Program

>

> Ortho-McNeil and FDA revised the WARNINGS and PRECAUTIONS sections of the

> prescribing information, notifying healthcare professionals that Topamax

> causes hyperchloremic, non-anion gap metabolic acidosis (decreased serum

> bicarbonate). Measurement of baseline and periodic serum bicarbonate

during

> topiramate treatment is recommended.

>

> Read the 2003 Medwatch safety summary, including links to the " Dear

> Healthcare Professional " letter and revised label, at:

>

> http://www.fda.gov/medwatch/SAFETY/2003/safety03.htm#topamax2

>

> --------

>

> Thank you for using MedWatch as a trusted source for timely safety

information on drugs and other medical products regulated by the U.S. Food

and Drug Administration. If you find this e-mail notification helpful,

please consider telling colleagues and friends about MedWatch. They can

learn more about us and subscribe/unsubscribe to the e-list at the MedWatch

homepage, http://www.fda.gov/medwatch or by going directly to

http://list.nih.gov/cgi-bin/wa?SUBED1=medwatch & A=1

>

> This is an automated message delivery system -- replying to this message

will not reach MedWatch staff. If you have comments or questions about

MedWatch or this e-mail, please contact us through our comments & feedback

web page, http://www.fda.gov/medwatch/feedback.htm

>